[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nosocomial-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nosocomial-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,82,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100553159","diagnostic-of-d-lactate-in-cerebrospinal-fluid-level-in-patients-with-suspected-ventriculostomy-related-meningitis-100553159",false,"NCT06482463","Diagnostic of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis","Diagnostic Significance of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis : a Pilot Study","TOTEM","Inclusion Criteria:\n\n* Age ⩾ 18 years.\n* Patient with an external ventriculostomy implanted at the Toulouse University Hospital.\n* Patient suspected of nosocomial meningitis due to a febrile syndrome (in the absence of any other identified infectious site), headache, nausea, lethargy, change in neurological status, meningeal syndrome, epileptic event and cutaneous or subcutaneous inflammation at the ventriculostomy site of insertion.\n* Patient having expressed oral consent, after free and informed information.\n* Patient affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* Diagnosis of community meningitis.\n* Proven or suspected meningitis and\u002For ventriculitis during the previous month.\n* Diagnosis of nosocomial meningitis made in another medical centre prior to admission.\n* Short bowel syndrome.\n* Acute mesenteric ischaemia.\n* End-stage renal failure (GFR \\\u003C 15 ml\u002Fmin\u002Fm2).\n* Peritoneal dialysis.\n* Patient participating in another research protocol with an exclusion period still in progress.\n* Pregnant or breastfeeding woman.\n* Patient under guardianship or trusteeship, persons placed under the protection of justice","ALL","18 Years",{"count":20,"type":21},185,"ESTIMATED","INTERVENTIONAL",[24],"NA","The TOTEM study is a single-center study designed to evaluate the performance of the D-lactate assay in cerebrospinal fluid (CSF) for the diagnosis of ventriculostomy-related nosocomial meningitis. The study will be conducted in the neurosurgical intensive care unit of the Toulouse University Hospital, in patients with a suspected diagnosis of ventriculostomy-related nosocomial meningitis.",[27],"Nosocomial Infection",[29,30,31],"External ventriculostomy","Nosocomial meningitis","Bacterial meningitis","RECRUITING","2025-12-23",{"date":35,"type":36},"2025-12-31","ACTUAL",{"date":38,"type":36},"2025-02-12",{"date":40,"type":21},"2027-02",{"name":42,"class":43},"University Hospital, Toulouse","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100539984","mechanical-insufflation-exsufflation-and-hypertonic-saline-in-nosocomial-bacterial-respiratory-tract-infection-100539984","NCT06310941","Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection","Aspiration of Bronchial Secretions With Mechanical Insufflation-Exsufflation and Hypertonic Saline in Bacterial Nosocomial Tracheobronchitis and Pneumonia in Intubated Patients.","ABSENTA","Inclusion Criteria:\n\n* Signed informed consent\n* Nosocomial pneumonia (vHAP or VAP) or nosocomial tracheobronchitis\n* Intubated with a cuffed endotracheal tube or tracheostomy cannula.\n\nExclusion Criteria:\n\n* Ominous prognosis\n* Frank hemoptisis\n* Barotrauma (pneumothorax or pneumomediastinum)\n* Bronchospasm (patients on bronchodilators for previous bronchospasm may be included\n* Unstable thoracic cage\n* Suspected unmonitored intracraneal hypertension",{"count":54,"type":21},100,[24],"Multicenter, randomized open label clinical trial to evaluate IEM and HS as concomitant therapy for respiratory tract infection in patients under artificial ventilation in the ICU.\n\nLung infection is a serious complication that may occur during hospital stay and may need artificial respiration or even develop during artificial ventilation for other causes.\n\nCurrent specific treatment consists of intravenous antibiotics. The current study evaluated whether aspiration and drainage of infected sputum helps curing this severe complication and whether nebulized HS has additional benefits, like loosening of secretions, eradicating bacteria or reducing inflammation.",[27,58,59,60,61],"Nosocomial Pneumonia","Tracheobronchitis","Mechanical Ventilation Complication","Endotracheal Intubation",[63,64,65,66,67,68,69,70],"mechanical insufflation-exsufflation","cough assist device","hypertonic saline","nosocomial respiratory tract infection","hospital-acquired pneumonia","tracheobronchitis","ventilator-associated pneumonia","nebulization","NOT_YET_RECRUITING","2025-03-21",{"date":74,"type":36},"2025-03-26",{"date":76,"type":21},"2026-01-01",{"date":78,"type":21},"2027-12-30",{"name":80,"class":43},"Hospital San Carlos, Madrid",8,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":44},"100574692","oseltamivir-and-baloxavir-marboxil-for-prophylaxis-against-influenza-under-a-hospital-based-setting-100574692","NCT06762587","Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting","A Randomized, Open-Label Clinical Study on the Efficacy of Baloxavir Marboxil and Oseltamivir for Post-Exposure Prevention of Influenza in a Hospital Setting","Inclusion Criteria:\n\n* Index patient:\n* 1\\. Patients or accompanying caregivers hospitalized at participating medical institutions.\n* 2.The subject and\u002For their legal guardian both agree to participate in this clinical study, sign the informed consent form, and are able to comply with the study requirements for follow-up and completion of all study procedures and assessments.\n* 3.Age ≥ 2 years.\n* 4.Influenza nucleic acid positivity confirmed by throat swab, sputum and other respiratory sample through rapid antigen testing (RAT) or PCR.\n* Close contact:\n* 1.Patients or accompanying caregivers hospitalized at participating medical institutions.\n* 2.The subject and\u002For their legal guardian both agree to participate in this clinical study, sign the informed consent form, and are able to comply with the study requirements for follow-up and complete all study procedures and assessments\n* 3.Age ≥ 12 years.\n* 4.Expected to remain hospitalized for ≥ 72 hours.\n* 5.The room must contain at least one hospitalized index patient diagnosed with influenza virus within the past 72 hours, and the contact is expected to stay with the hospitalized index patient in the ward for more than 24 hours.\n* 6.Throat swab on the first day tested negative for influenza virus by PCR.\n\nExclusion Criteria:\n\n* Close contacts\n* 1.With known allergies to the active ingredients or excipients of the investigational drug.\n* 2.Close contacts diagnosed with or having experienced an influenza virus infection within the past 12 weeks.\n* 3.Close contacts who have used antiviral drugs (including neuraminidase inhibitors, hemagglutinin inhibitors, and M2 ion channel blockers, such as oseltamivir, zanamivir, peramivir, favipiravir, abidol, baloxavir marboxil, amantadine, rimantadine, or any other antiviral drugs approved by NMPA) within the 2 weeks prior to screening.\n* 4.Close contacts known to be pregnant or breastfeeding.\n* 5\\. Having experienced fever (axillary temperature ≥37.3°C) in the past 3 days prior to screening.\n* 6.Subjects deemed unsuitable to participate in the study by the investigator.",true,"2 Years",{"count":92,"type":21},372,[24],"This study aims to randomly assign close contacts of hospitalized influenza virus patients to receive baloxavir marboxil prophylaxis, oseltamivir prophylaxis or no antiviral prophylaxis and monitor the incidence of clinical influenza, evaluating the prophylaxis efficiency of antivirals in a hospital setting.",[96,97,27],"Influenza","Influenza Prophylaxis",[99,100,101,102,103],"influenza","influenza prophylaxis","baloxavir marboxil","oseltamivir","nosocomial infection","2025-01-06",{"date":106,"type":36},"2025-01-07",{"date":108,"type":21},"2025-01-05",{"date":110,"type":21},"2025-05-05",{"name":112,"class":43},"Capital Medical University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":124,"conditions":125,"keywords":133,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":44},"100574372","hierarchy-of-effects-of-laboratory-markers-and-their-interaction-with-comorbidity-concerning-outcome-and-personalized-treatment-of-trauma-patients-in-emergency-care-and-rehabilitation-100574372","NCT06758427","Hierarchy of Effects of Laboratory Markers and Their Interaction With Comorbidity Concerning Outcome and Personalized Treatment of Trauma Patients in Emergency Care and Rehabilitation","HELICOPTER","Inclusion Criteria:\n\n* acute long bone fracture (humerus, ulna, radius, femur, tibia) with surgical treatment\n\nExclusion Criteria:\n\n* associated severe injury (ISS \\> 16)\n* associated traumatic brain injury\n* associated traumatic spine injury\n* dementia","67 Years",{"count":122,"type":21},2300,"OBSERVATIONAL","At least ten percent of trauma patients suffer from any sort of complication. The study aims to identify a risk factor profile to early identify trauma patients at risk.",[126,127,128,129,130,131,132,27],"Postoperative Complications","Surgical Site Infection","Wound Infection","Non-healing Wound","Pseudarthrosis","Bone Infection","Pneumonia",[134],"long bone fracture, trauma","2024-12-27",{"date":137,"type":36},"2025-01-03",{"date":139,"type":21},"2025-02-01",{"date":141,"type":21},"2027-10-31",{"name":143,"class":43},"Department of Trauma and Reconstructive Surgery at Eberhard Karls University Tuebingen, BG Klinik Tu"]